TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25074252

Group type: EXPERIMENTAL
Intervention: Aspirin reload (325 mg orally)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no reload)
Number of subjects: 91
Study: 22815989

Group type: EXPERIMENTAL
Intervention: Polypill (amlodipine 2.5 mg, losartan 25 mg, hydrochlorothiazide 12.5 mg, simvastatin 40 mg)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 19717646

Group type: EXPERIMENTAL
Intervention: Ketoprofen (300 mg/day for 5 days)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 17300594

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg twice daily (b.i.d.)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 15144392

Group type: EXPERIMENTAL
Intervention: 20% ALA preparation in Eucerin cream applied under an occlusive dressing followed by irradiation with 75 J/cm² of broad-band red light.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group treated with only light or only ALA.
Number of subjects: 9
Study: 11176160

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Continuous rotational therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Inhaled nitric oxide (NO) therapy
Number of subjects: 26
Study: 9498634

Group type: EXPERIMENTAL
Intervention: Genetically targeted prediction strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pure immunological strategy
Number of subjects: 0
Study: 8567093

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 200 mg/week
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (baseline measurements before injections)
Number of subjects: 36
Study: 2293809

Group type: EXPERIMENTAL
Intervention: Multiple component smoking cessation program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 13088

Group type: EXPERIMENTAL
Intervention: Alpha-wave biofeedback training (10 hour-long sessions over 3 weeks)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Alpha-wave biofeedback training
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (matched)
Number of subjects: 25
Study: 30230970

Group type: EXPERIMENTAL
Intervention: Single-session positive cognitive intervention
Number of subjects: 79
Study: 28781130

Group type: EXPERIMENTAL
Intervention: Intramyocardial application of 0.5‐5×10^6 CD133+
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (5ml)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Responders (R) classified by ∆LVEF≥5% after 180d
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Non-responders (NR)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Mean survival time for responders (R)
Number of subjects: 82
Study: 25298176

Group type: EXPERIMENTAL
Intervention: Higher levels of interleukin-6 at baseline
Number of subjects: 3794

Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability in blood pressure
Number of subjects: 3794

Group type: EXPERIMENTAL
Intervention: Markers of endothelial function, renal function, and glucose homeostasis
Number of subjects: 3794
Study: 23157368

Group type: EXPERIMENTAL
Intervention: ResMed continuous-positive-airway-pressure mask (CM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard mask (SM)
Number of subjects: 30
Study: 22072367

Group type: EXPERIMENTAL
Intervention: BREAD meal (2.39 MJ, with equal caloric distribution including bread)
Number of subjects: 122

Group type: COMPARATOR
Intervention: NO BREAD meal (2.40 MJ, with equal caloric distribution excluding bread)
Number of subjects: 122
Study: 19300425

Group type: EXPERIMENTAL
Intervention: L-arginine (3 x 7 g/day)
Number of subjects: 12
Study: 17542207

Group type: EXPERIMENTAL
Intervention: Direct resin composite restorations (Z‐250)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Indirect resin composite restorations (Z‐250 and RelyX)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ceramic inlays (Vitadur Alpha)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Conventional amalgam restorations (GS‐80)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bonded amalgam restorations
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (human caries-free premolars)
Number of subjects: 50
Study: 14767023

Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol injection therapy (PEIT)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Calcitriol injection therapy (PCIT)
Number of subjects: 19
Study: 11434842

Group type: EXPERIMENTAL
Intervention: Family‐to‐Family Network intervention (15-month duration)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Family‐to‐Family Network intervention
Number of subjects: 193
Study: 9733503

Group type: EXPERIMENTAL
Intervention: Substance P antagonist MK-869
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7912347

Group type: EXPERIMENTAL
Intervention: 0.7 mg/kg cladribine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cladribine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 1933601

Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin (200 IU) plus calcium (500 mg) daily for 3 years or 4 years
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin (200 IU) plus calcium (500 mg) daily for 3 years
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin (200 IU) plus calcium (500 mg) daily for 2 years
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin (200 IU) plus calcium (500 mg) daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 319936

Group type: EXPERIMENTAL
Intervention: Fenfluramine, 120 mg/day for 10 or more days
Number of subjects: 0
Study: 31609714

Group type: EXPERIMENTAL
Intervention: Bilateral motor priming
Number of subjects: 16

Group type: COMPARATOR
Intervention: Health care education followed by task specific training
Number of subjects: 16
Study: 31585425

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (5-ALA)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Sodium fluorescein (fluorescein)
Number of subjects: 209
Study: 28426239

Group type: EXPERIMENTAL
Intervention: Artificial pancreas (AP) system using the DiAs Control Platform software
Number of subjects: 12

Group type: COMPARATOR
Intervention: Usual insulin pump + continuous glucose monitor (CGM) care at home
Number of subjects: 12
Study: 25354554

Group type: EXPERIMENTAL
Intervention: Post-operative radiotherapy
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: CMF chemotherapy
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Interaction between chemotherapy and genotype
Number of subjects: 306
Study: 23821768

Group type: EXPERIMENTAL
Intervention: Risperidone or olanzapine dose reduction (50% in 4 weeks, maintained thereafter)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Maintenance group (dose kept constant)
Number of subjects: 61
Study: 16197959

Group type: EXPERIMENTAL
Intervention: Enriched training (interactive web tutorial and live remote observation)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional training (overview of scoring conventions, watching and scoring videotapes, observation of interviews)
Number of subjects: 12
Study: 12827399

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10328247

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 0
Study: 8682758

Group type: EXPERIMENTAL
Intervention: Clinician-facilitated, manual-based, psychoeducational preventive intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standardized lecture-group discussion
Number of subjects: 54
Study: 1514532

Group type: EXPERIMENTAL
Intervention: Calcium chloride administration
Number of subjects: 5
Study: 6151503

Group type: EXPERIMENTAL
Intervention: Antihypertensive regimens containing a beta-blocker (oxprenolol)
Number of subjects: 6357

Group type: COMPARATOR
Intervention: Antihypertensive therapy not containing a beta-blocker
Number of subjects: 6357
Study: 31706300

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks (Q2W)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study: 27569432

Group type: EXPERIMENTAL
Intervention: Suspicious digital rectal examination
Number of subjects: 35350

Group type: EXPERIMENTAL
Intervention: Abnormal prostate specific antigen (4 ng/ml or greater)
Number of subjects: 35350

Group type: EXPERIMENTAL
Intervention: Suspicious digital rectal examination and abnormal prostate specific antigen (combined)
Number of subjects: 35350

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 35350

Group type: EXPERIMENTAL
Intervention: Clinically significant prostate cancers detected
Number of subjects: 35350

Group type: EXPERIMENTAL
Intervention: Prostate cancer specific deaths
Number of subjects: 35350
Study: 25356632

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (400-800 mg/day)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Risperidone (4-6 mg/day)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 114
Study: 23786762

Group type: EXPERIMENTAL
Intervention: Low-fat yoghurt with 1.9 g/d plant stanols as esters
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo yoghurt
Number of subjects: 70
Study: 21669582

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 60
Study: 19941671

Group type: EXPERIMENTAL
Intervention: Surgeon-performed ultrasound
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (no ultrasound)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 800
Study: 16523249

Group type: EXPERIMENTAL
Intervention: Children in foster care
Number of subjects: 182
Study: 12972102

Group type: EXPERIMENTAL
Intervention: MC-1 treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10732848

Group type: EXPERIMENTAL
Intervention: HMG-CoA reductase inhibitor (simvastatin)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 15
Study: 9206241

Group type: EXPERIMENTAL
Intervention: Zhinu (ZN) ‐I, ‐II
Number of subjects: 61

Group type: COMPARATOR
Intervention: prednisone
Number of subjects: 61
Study: 1358218

Group type: EXPERIMENTAL
Intervention: Immediate opening of colostomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed opening of colostomy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 6199602

Group type: EXPERIMENTAL
Intervention: Ketanserin (3 X 40 mg daily for 6 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ketanserin (single oral dose of 40 mg)
Number of subjects: 14
Study: 29898009

Group type: EXPERIMENTAL
Intervention: Juvenile fibromyalgia (JFM)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Polyarticular juvenile idiopathic arthritis (JIA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 150
Study: 30238438

Group type: EXPERIMENTAL
Intervention: Duct endoscopy
Number of subjects: 66

Group type: COMPARATOR
Intervention: No duct endoscopy
Number of subjects: 66
Study: 26749408

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg intravenously
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg orally
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rifampin 600 mg once daily
Number of subjects: 20
Study: 24989620

Group type: EXPERIMENTAL
Intervention: SPIRIT intervention (1-year programme including audit, feedback, goal setting, leadership programme, staff training, testing systems, exchange with researchers)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (agencies not receiving the intervention during the initial phase)
Number of subjects: 6
Study: 22201295

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg (15-minute infusion)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Flucloxacillin 2 g (5-minute infusion)
Number of subjects: 24
Study: 20063994

Group type: EXPERIMENTAL
Intervention: 400 microg misoprostol 3‐hourly (group A)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 600 microg misoprostol 6‐hourly (group B)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 800 microg misoprostol 12‐hourly (group C)
Number of subjects: 118
Study: 17727927

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by radical surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various drug regimens for neoadjuvant chemotherapy
Number of subjects: 0
Study: 16084162

Group type: EXPERIMENTAL
Intervention: Anteroposterior (AP) electrode position
Number of subjects: 123

Group type: COMPARATOR
Intervention: Anterolateral (AL) electrode position
Number of subjects: 123
Study: 12693427

Group type: EXPERIMENTAL
Intervention: Amisulpride (50-300 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10408059

Group type: EXPERIMENTAL
Intervention: Supine Position (SP)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Lateral Position (LP)
Number of subjects: 56
Study: 7591492

Group type: EXPERIMENTAL
Intervention: Standard weekly intervention (6 weekly sessions)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Weekend intensive (2-day program)
Number of subjects: 156
Study: 1981077

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 47
Study: 6794980

Group type: EXPERIMENTAL
Intervention: Nordette (30 microgram ethinyl estradiol and 150 microgram d-norgestrel)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nordiol (50 microgram ethinyl estradiol and 250 microgram d-norgestrel)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Biphasil (50 microgram ethinyl estradiol and 50 microgram d-norgestrel X 11 days and 125 microgram d-norgestrel X 10 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-treatment (control)
Number of subjects: 36
Study: 31220085

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Predictive model based on heart rate terms, mid-upper arm circumference, malaria status, water source, family income, and sibling childcare status
Number of subjects: 526
Study: 28345400

Group type: EXPERIMENTAL
Intervention: A‐mix (3 g/dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (3 g of dextrin/dose)
Number of subjects: 10
Study: 25496283

Group type: EXPERIMENTAL
Intervention: Usual care family therapy (UC-FT)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Nonfamily treatment (UC-Other)
Number of subjects: 205
Study: 23967066

Group type: EXPERIMENTAL
Intervention: L-arginine 6.0 g daily for 8 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo L-arginine for 8 weeks
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Vitamin D 50,000 IU 4-weekly for 8 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo vitamin D for 8 weeks
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Clinical score (weight, FEV1, cough, sputum, haemoptysis)
Number of subjects: 200
Study: 21890081

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-fat Therapeutic Lifestyle Changes Diet (TLCD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both MD and TLCD
Number of subjects: 40
Study: 19570145

Group type: EXPERIMENTAL
Intervention: Early initiation of entacapone with levodopa/DDCI
Number of subjects: 488

Group type: COMPARATOR
Intervention: Delayed initiation of entacapone with levodopa/DDCI (placebo)
Number of subjects: 488
Study: 17949458

Group type: EXPERIMENTAL
Intervention: 10 min ischemic preconditioning (IPC)
Number of subjects: 101

Group type: COMPARATOR
Intervention: No IPC
Number of subjects: 101
Study: 15119641

Group type: EXPERIMENTAL
Intervention: Fibrin glue sealant (1 mL applied to the peritoneal cuff suture)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no fibrin glue sealant)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fibrin glue sealant
Number of subjects: 45

Group type: COMPARATOR
Intervention: Fibrin glue sealant and Control group
Number of subjects: 45
Study: 11499330

Group type: EXPERIMENTAL
Intervention: Oral terbinafine 250 mg once daily for 1 or 2 weeks
Number of subjects: 14
Study: 9160490

Group type: EXPERIMENTAL
Intervention: Older ad hoc methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recent statistical methods for multiple event data
Number of subjects: 0
Study: 8425702

Group type: EXPERIMENTAL
Intervention: 12.5 mg captopril
Number of subjects: 0
Study: 3118827

Group type: EXPERIMENTAL
Intervention: TPN supplemented with ornithine‐alpha‐ketoglutarate (0.35 g/kg bw/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: TPN only (Control)
Number of subjects: 15
Study: 31747326

Group type: EXPERIMENTAL
Intervention: EGCG (440 μM) administered at first onset of ARIE and then weekly after final radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGCG (440 μM) administered for ARIE
Number of subjects: 0
Study: 30112772

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg as first-line treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tolterodine 4 mg as first-line treatment
Number of subjects: 0
Study: 26316552

Group type: EXPERIMENTAL
Intervention: Group therapy task training (GT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Individual task training (IT)
Number of subjects: 73
Study: 25577723

Group type: EXPERIMENTAL
Intervention: Atorvastatin plus ezetimibe (10 mg) daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin monotherapy
Number of subjects: 0
Study: 24314222

Group type: EXPERIMENTAL
Intervention: rh-endostatin (Endostar) combined with docetaxel
Number of subjects: 68

Group type: COMPARATOR
Intervention: Single docetaxel
Number of subjects: 68
Study: 20575193

Group type: EXPERIMENTAL
Intervention: Amorphous calcium phosphate-containing composite resin (ACP-containing)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional composite resin (Control)
Number of subjects: 40
Study: 18394501

Group type: EXPERIMENTAL
Intervention: Treatment group TRP(8)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham group TRP(8)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group TRP(8)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Treatment group TRP(30)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham group TRP(30)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group TRP(30)
Number of subjects: 66
Study: 17109664

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.25-1 mg daily
Number of subjects: 243

Group type: COMPARATOR
Intervention: Non-steroidal conventional asthma therapy (NSCAT)
Number of subjects: 243
Study: 12891539

Group type: EXPERIMENTAL
Intervention: Oral tacrolimus 0.2 mg. kg(‐1). day(‐1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 10492065

Group type: EXPERIMENTAL
Intervention: Vincristine, Prednisone, and L-asparaginase (VPL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: VPL plus anthracyclines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VPL with an anti-CD19 immunotoxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anthracyclines
Number of subjects: 0
Study: 8731073

Group type: EXPERIMENTAL
Intervention: Natural light treatment (1‐h morning walk outdoors)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low‐dose artificial light (0.5 h@2800 lux)
Number of subjects: 0
Study: 1836687

Group type: EXPERIMENTAL
Intervention: 3 chemotherapeutic regimens at 3-monthly intervals
Number of subjects: 0
Study: 6125287

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (self-control)
Number of subjects: 15
Study: 2870548

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate 100 mg per day for two months
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 28646480

Group type: EXPERIMENTAL
Intervention: Masculine play behavior
Number of subjects: 412

Group type: COMPARATOR
Intervention: Control play behavior
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Feminine play behavior
Number of subjects: 412
Study: 26944263

Group type: EXPERIMENTAL
Intervention: Care Programme for the Last Days of Life
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Care Guide for the Last Days of Life
Number of subjects: 57
Study: 24592170

Group type: EXPERIMENTAL
Intervention: Individualized dietetic intervention
Number of subjects: 101
Study: 22316141

Group type: EXPERIMENTAL
Intervention: 6-weekly group-based skills training for adolescents followed by 6-weekly targeted newsletters for caregivers (Group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group-based skills training for adolescents only (Group 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 0
Study: 20650921

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 30
Study: 19119677

Group type: EXPERIMENTAL
Intervention: Rapid Rhino Stammberger sinus dressing (RR)
Number of subjects: 24
Study: 15931068

Group type: EXPERIMENTAL
Intervention: 10% cinnamaldehyde
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40% menthol
Number of subjects: 10
Study: 12716275

Group type: EXPERIMENTAL
Intervention: Venlafaxine (N = 851)
Number of subjects: 2046

Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs) (N = 749)
Number of subjects: 2046

Group type: COMPARATOR
Intervention: Placebo (N = 446)
Number of subjects: 2046
Study: 10348423

Group type: EXPERIMENTAL
Intervention: Smoking (2 filter cigarettes over 10 minutes)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nonsmoking
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 10